Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.30M | -- | 100.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.30M | -- | 100.00K | -- |
| Cost of Revenue | 28.54M | 22.27M | 36.88M | 59.27M | 38.89M |
| Gross Profit | -28.54M | -20.97M | -36.88M | -59.17M | -38.89M |
| SG&A Expenses | 5.28M | 6.42M | 6.02M | 31.90M | 7.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.81M | 28.69M | 42.90M | 91.17M | 46.80M |
| Operating Income | -33.81M | -27.39M | -42.90M | -91.07M | -46.80M |
| Income Before Tax | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M |
| Income Tax Expenses | -- | 2.00K | -- | 0.00 | -- |
| Earnings from Continuing Operations | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M |
| EBIT | -33.81M | -27.39M | -42.90M | -91.07M | -46.80M |
| EBITDA | -33.23M | -26.73M | -42.23M | -90.38M | -46.04M |
| EPS Basic | -2.28 | -1.85 | -2.80 | -3.09 | -2.84 |
| Normalized Basic EPS | -1.42 | -1.16 | -1.75 | -3.60 | -1.77 |
| EPS Diluted | -2.28 | -1.85 | -2.80 | -3.10 | -2.84 |
| Normalized Diluted EPS | -1.42 | -1.16 | -1.75 | -3.60 | -1.77 |
| Average Basic Shares Outstanding | 15.48M | 15.47M | 15.47M | 15.47M | 15.47M |
| Average Diluted Shares Outstanding | 15.48M | 15.47M | 15.47M | 15.47M | 15.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |